Европейский союз -
исландский -
EMA (European Medicines Agency)
lextemy
mylan ire healthcare limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - Æxlishemjandi lyf - treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.
Исландия -
исландский -
LYFJASTOFNUN (Icelandic Medicines Agency)
oxcarbazepin jubilant filmuhúðuð tafla 600 mg
jubilant pharmaceuticals nv - oxcarbazepinum inn - filmuhúðuð tafla - 600 mg
Исландия -
исландский -
LYFJASTOFNUN (Icelandic Medicines Agency)
oxcarbazepin jubilant filmuhúðuð tafla 300 mg
jubilant pharmaceuticals nv - oxcarbazepinum inn - filmuhúðuð tafla - 300 mg
Исландия -
исландский -
LYFJASTOFNUN (Icelandic Medicines Agency)
trileptal mixtúra, dreifa 60 mg/ml
novartis healthcare a/s - oxcarbazepinum inn - mixtúra, dreifa - 60 mg/ml
Исландия -
исландский -
LYFJASTOFNUN (Icelandic Medicines Agency)
trileptal filmuhúðuð tafla 600 mg
novartis healthcare a/s - oxcarbazepinum inn - filmuhúðuð tafla - 600 mg
Исландия -
исландский -
LYFJASTOFNUN (Icelandic Medicines Agency)
trileptal filmuhúðuð tafla 300 mg
novartis healthcare a/s - oxcarbazepinum inn - filmuhúðuð tafla - 300 mg
Исландия -
исландский -
LYFJASTOFNUN (Icelandic Medicines Agency)
trileptal filmuhúðuð tafla 150 mg
novartis healthcare a/s - oxcarbazepinum inn - filmuhúðuð tafla - 150 mg
Исландия -
исландский -
LYFJASTOFNUN (Icelandic Medicines Agency)
oxaliplatin actavis innrennslisþykkni, lausn 5 mg/ml
actavis group ptc ehf. - oxaliplatinum inn - innrennslisþykkni, lausn - 5 mg/ml
Исландия -
исландский -
LYFJASTOFNUN (Icelandic Medicines Agency)
pemetrexed wh (pemetrexed synthon) innrennslisþykkni, lausn 25 mg/ml
williams & halls ehf. - pemetrexedum inn - innrennslisþykkni, lausn - 25 mg/ml
Европейский союз -
исландский -
EMA (European Medicines Agency)
degarelix accord
accord healthcare s.l.u. - degarelix acetate - blöðruhálskirtli - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.